United States - English - NLM (National Library of Medicine)

king bio inc. - official hpus: adrenalinum, anacardium orientale, blatta orientalis, formalinum, fumaria officinalis, glycerinum, graphites, magnesia muriatica, natrum pyruvicum, nitricum acidum, pituitarum posterium, phosphorus, phytolacca decandra, pulsatilla and sulphur., reference image cosmetic.jpg - uses for temporary relief of symptoms from cosmetics and household chemicals: - headaches - skin irritations - respiratory difficulties - body aches and pains - fatigue - difficulty sleeping - dizziness and nausea uses for temporary relief of symptoms from cosmetics and household chemicals: headaches, skin irritations, respiratory difficulties, body aches and pains, fatigue, difficulty sleeping, dizziness and nausea. reference image cosmetic.jpg

European Union - English - EMA (European Medicines Agency)

seqirus s.r.l.  - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza, human; immunization; disease outbreaks - vaccines - active immunisation against h5n1 subtype of influenza-a virus.this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/turkey/turkey/1/05 (h5n1)-like strain.aflunov should be used in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v. - daptomycin - gram-positive bacterial infections; bacteremia; soft tissue infections; endocarditis, bacterial - antibacterials for systemic use, - cubicin is indicated for the treatment of the following infections.adult and paediatric (1 to 17 years of age) patients with complicated skin and soft-tissue infections (cssti).adult patients with right-sided infective endocarditis (rie) due to staphylococcus aureus.it is recommended that the decision to use daptomycin should take into account the antibacterial susceptibility of the organism and should be based on expert advice.adult and paediatric (1 to 17 years of age) patients with staphylococcus aureus bacteraemia (sab). in adults, use in bacteraemia should be associated with rie or with cssti, while in paediatric patients, use in bacteraemia should be associated with cssti.daptomycin is active against gram positive bacteria only. in mixed infections where gram negative and/or certain types of anaerobic bacteria are suspected, cubicin should be co-administered with appropriate antibacterial agent(s). consideration should be given to official guidance on the appropriate use of antibacterial agents.

European Union - English - EMA (European Medicines Agency)

seqirus s.r.l.  - influenza virus surface antigens, inactivated: a/viet nam/1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - influenza vaccines - prophylaxis of influenza in an officially declared pandemic situation.pandemic influenza vaccine should be used in accordance with official guidance.

European Union - English - EMA (European Medicines Agency)

bayer animal health gmbh - imidacloprid, moxidectin - antiparasitic products, insecticides and repellents - dogs; cats; ferrets - dogsfor dogs suffering from, or at risk from, mixed parasitic infections:the treatment and prevention of flea infestation (ctenocephalides felis),the treatment of biting lice (trichodectes canis),the treatment of ear mite infestation (otodectes cynotis), sarcoptic mange (caused by sarcoptes scabiei var. canis), demodicosis (caused by demodex canis),the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),the treatment of circulating microfilariae (dirofilaria immitis),the treatment of cutaneous dirofilariosis (adult stages of dirofilaria repens)the prevention of cutaneous dirofilariosis (l3 larvae of dirofilaria repens),the reduction of circulating microfilariae (dirofilaria repens),the prevention of angiostrongylosis (l4 larvae and immature adults of angiostrongylus vasorum),the treatment of angiostrongylus vasorum and crenosoma vulpis,the prevention of spirocercosis (spirocerca lupi),the treatment of eucoleus (syn. capillaria) boehmi (adults),the treatment of the eye worm thelazia callipaeda (adults),the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara canis, ancylostoma caninum and uncinaria stenocephala, adults of toxascaris leonina and trichuris vulpis).the product can be used as part of a treatment strategy for flea allergy dermatitis (fad).catsfor cats suffering from, or at risk from, mixed parasitic infections:the treatment and prevention of flea infestation (ctenocephalides felis),the treatment of ear mite infestation (otodectes cynotis),the treatment of notoedric mange (notoedres cati),the treatment of the lungworm eucoleus aerophilus (syn. capillaria aerophila) (adults),the prevention of lungworm disease (l3/l4 larvae of aelurostrongylus abstrusus),the treatment of the lungworm aelurostrongylus abstrusus (adults),the treatment of the eye worm thelazia callipaeda (adults),the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis),the treatment of infections with gastrointestinal nematodes (l4 larvae, immature adults and adults of toxocara cati and ancylostoma tubaeforme).the product can be used as part of a treatment strategy for flea allergy dermatitis (fad).ferretsfor ferrets suffering from, or at risk from, mixed parasitic infections:the treatment and prevention of flea infestation (ctenocephalides felis),the prevention of heartworm disease (l3 and l4 larvae of dirofilaria immitis).

European Union - English - EMA (European Medicines Agency)

laboratorios hipra, s.a. - live attenuated infectious bursal disease virus (ibdv), strain 1052 - immunologicals for aves, domestic fowl, live viral vaccines, avian infectious bursal disease virus (gumboro disease) - chicken; embryonated chicken eggs - for active immunisation of 1-day-old broiler chicks and embryonated broiler chicken eggs to reduce clinical signs and lesions of the bursa of fabricius caused by very virulent avian infectious bursal disease virus infection.

European Union - English - EMA (European Medicines Agency)

sanofi pasteur - neisseria meningitidis group c polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group a polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group y polysaccharide conjugated to tetanus toxoid, neisseria meningitidis group w-135 polysaccharide conjugated to tetanus toxoid - meningitis, meningococcal - vaccines - menquadfi is indicated for active immunisation of individuals from the age of 12 months and older against invasive meningococcal disease caused by neisseria meningitidis serogroups a, c, w, and y.the use of this vaccine should be in accordance with available official recommendations.

European Union - English - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccines - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty original/omicron ba.1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19.comirnaty original/omicron ba.4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.comirnaty original/omicron ba.4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.comirnaty original/omicron ba.4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba.4-5 (1.5/1.5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. comirnaty omicron xbb.1.5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.comirnaty omicron xbb.1.5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.comirnaty omicron xbb.1.5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.comirnaty omicron xbb.1.5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.the use of this vaccine should be in accordance with official recommendations.

European Union - English - EMA (European Medicines Agency)

orion corporation - tasipimidine sulfate - other hypnotics and sedatives - dogs - alleviation of situational anxiety and fear in dogs triggered by e.g. travel, noise, owner departure, veterinary visits.

European Union - English - EMA (European Medicines Agency)

merck sharp & dohme b.v.  - pneumococcal polysaccharide conjugate vaccine (adsorbed) - pneumococcal infections - pneumococcus, purified polysaccharides antigen conjugated - vaxneuvance is indicated for active immunisation for the prevention of invasive disease, pneumonia and acute otitis media caused by streptococcus pneumoniae in infants, children and adolescents from 6 weeks to less than 18 years of age.vaxneuvance is indicated for active immunisation for the prevention of invasive disease and pneumonia caused by streptococcus pneumoniae in individuals 18 years of age and older. see sections 4.4 and 5.1 for information on protection against specific pneumococcal serotypes.the use of vaxneuvance should be in accordance with official recommendations.